136 related articles for article (PubMed ID: 31027688)
21. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
[TBL] [Abstract][Full Text] [Related]
22. KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.
Renaud S; Guerrera F; Seitlinger J; Reeb J; Voegeli AC; Legrain M; Mennecier B; Santelmo N; Falcoz PE; Quoix E; Chenard MP; Weingertner N; Beau-Faller M; Massard G
Clin Lung Cancer; 2018 Nov; 19(6):e919-e931. PubMed ID: 30217639
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.
Saruwatari K; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ohe Y; Goto K
Clin Lung Cancer; 2016 Nov; 17(6):581-587. PubMed ID: 27424806
[TBL] [Abstract][Full Text] [Related]
25. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
Abdel-Rahman O
Clin Respir J; 2018 Oct; 12(10):2519-2524. PubMed ID: 30073795
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
[TBL] [Abstract][Full Text] [Related]
29. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
30. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.
Hiltermann TJN; Pore MM; van den Berg A; Timens W; Boezen HM; Liesker JJW; Schouwink JH; Wijnands WJA; Kerner GSMA; Kruyt FAE; Tissing H; Tibbe AGJ; Terstappen LWMM; Groen HJM
Ann Oncol; 2012 Nov; 23(11):2937-2942. PubMed ID: 22689177
[TBL] [Abstract][Full Text] [Related]
32. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.
Schabath MB; Nguyen A; Wilson P; Sommerer KR; Thompson ZJ; Chiappori AA
Lung Cancer; 2014 Oct; 86(1):14-21. PubMed ID: 25115410
[TBL] [Abstract][Full Text] [Related]
33. [Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
Li HM; Yuan P; Yu DK; Ma F; Tan WW; Feng T; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):504-9. PubMed ID: 27531263
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Imai H; Mori K; Watase N; Fujimoto S; Kaira K; Yamada M; Minato K
Can Respir J; 2016; 2016():5405810. PubMed ID: 27445549
[TBL] [Abstract][Full Text] [Related]
36. Third-line chemotherapy in small-cell lung cancer: an international analysis.
Simos D; Sajjady G; Sergi M; Liew MS; Califano R; Ho C; Leighl N; White S; Summers Y; Petrcich W; Wheatley-Price P
Clin Lung Cancer; 2014 Mar; 15(2):110-8. PubMed ID: 24365050
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
38. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV;
N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641
[TBL] [Abstract][Full Text] [Related]
39. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Lee SM; Woll PJ; Rudd R; Ferry D; O'Brien M; Middleton G; Spiro S; James L; Ali K; Jitlal M; Hackshaw A
J Natl Cancer Inst; 2009 Aug; 101(15):1049-57. PubMed ID: 19608997
[TBL] [Abstract][Full Text] [Related]
40. [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Yashiki C; Hirose T; Sugiyama T; Kusumoto S; Shirai T; Ohmori T; Adachi M; Nakamura A
Gan To Kagaku Ryoho; 2010 Feb; 37(2):245-9. PubMed ID: 20154478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
